Literature DB >> 9775530

Effect of growth factors on expression of integrin subtypes in microvascular endothelial cells isolated from bovine retinas.

H Enaida1, T Ito, Y Oshima, T Sakamoto, K Yago, K Kato, H Kochi.   

Abstract

We isolated microvascular endothelial cells from bovine retinas (BREC) by a colony isolation method, and investigated the effects of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) on growth as well as integrin subtype expression of the cultured BREC. Either of the growth factors stimulated growth of the cultured BREC. In non-stimulated BREC, alpha v beta 3 integrin expression was predominant over the other integrin subtypes tested (alpha v beta 5, alpha 2 beta 1 and alpha 5 beta 1), but no enhancement of the alpha v beta 3 expression occurred by either growth factor stimulation. On the other hand, bFGF addition stimulated alpha v beta 5 and alpha 5 beta 1 expression while VEGF induced the alpha 2 beta 1 expression as well. These results suggest that external stimuli such as bFGF and VEGF alter integrin expression profiles of BREC and probably influence interactions of endothelial cells with extracellular matrix during angiogenesis which must be involved in pathogenesis of ischemic retinal disorders. In this respect, this BREC culture system could be useful to study the mechanism of neovascularization in these disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9775530

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  2 in total

1.  ATN-161 as an Integrin α5β1 Antagonist Depresses Ocular Neovascularization by Promoting New Vascular Endothelial Cell Apoptosis.

Authors:  Ailing Sui; Yisheng Zhong; Anna M Demetriades; Jikui Shen; Ting Su; Yiyun Yao; Yushuo Gao; Yanji Zhu; Xi Shen; Bing Xie
Journal:  Med Sci Monit       Date:  2018-08-22

2.  Integrin α5β1-Ang1/Tie2 receptor cross-talk regulates brain endothelial cell responses following cerebral ischemia.

Authors:  Defang Pang; Lu Wang; Jing Dong; Xiaoyin Lai; Qijuan Huang; Richard Milner; Longxuan Li
Journal:  Exp Mol Med       Date:  2018-09-05       Impact factor: 8.718

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.